Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBenitez Hidalgo, Olga
dc.contributor.authorMartinez Garcia, Maria Fernanda
dc.contributor.authorBescós Cabestre, Agustí
dc.contributor.authorJuarez Giménez, Juan Carlos
dc.contributor.authorGironella Mesa, Mercedes
dc.contributor.authorBosch Albareda, Francesc
dc.date.accessioned2022-09-07T12:11:18Z
dc.date.available2022-09-07T12:11:18Z
dc.date.issued2022-05
dc.identifier.citationBenitez Hidalgo O, Martinez Garcia MF, Bescos Cabestre A, Juarez Gimenez JC, Gironella Mesa M, Bosch Albareda F. Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management. Clin Case Reports. 2022 May;10(5):e05848.
dc.identifier.issn2050-0904
dc.identifier.urihttp://hdl.handle.net/11351/8056
dc.descriptionAnesthesia; Haemophilia B; Neurosurgery
dc.description.abstractExtended half-life FIX (EHL-FIX) concentrates have been developed with the purpose of reducing the frequency of infusions in patients with severe or moderate hemophilia B. We describe the case of a 63-year-old patient with severe hemophilia B (sHB) treated with FIX-Fc fusion protein (rFIXFc) who underwent neurosurgery.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesClinical Case Reports;10(5)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectSistema nerviós - Cirurgia
dc.subjectHemofília - Tractament
dc.subjectProteïnes recombinants - Ús terapèutic
dc.subject.meshHemophilia B
dc.subject.mesh/drug therapy
dc.subject.meshNeurosurgery
dc.subject.meshRecombinant Fusion Proteins
dc.titleNeurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1002/ccr3.5848
dc.subject.decshemofilia B
dc.subject.decs/farmacoterapia
dc.subject.decsneurocirugía
dc.subject.decsproteínas de fusión recombinantes
dc.relation.publishversionhttps://doi.org/10.1002/ccr3.5848
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Benitez Hidalgo O, Martinez Garcia MF, Gironella Mesa M, Bosch Albareda F] Experimental Hematology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Bescos Cabestre A] Servei de Neurocirurgia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Juarez Gimenez JC] Servei de Farmàcia Hospitalària, Vall d'Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid35620255
dc.identifier.wos000798984900001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record